Evaluation of Parafoveal Retinal Function in Epiretinal Membrane Foveoschisis: A Pilot Study Comparing ERM Phenotypes via MP-3 Microperimetry - Takeaways - MDSpire

Evaluation of Parafoveal Retinal Function in Epiretinal Membrane Foveoschisis: A Pilot Study Comparing ERM Phenotypes via MP-3 Microperimetry

  • By

  • Reio Sekine

  • Tatsuya Jujo

  • Kota Kakehashi

  • Kaito Tomokiyo

  • Naoto Uchiyama

  • Naoto Tokuda

  • Hiroshi Toshida

  • Yasushi Kitaoka

  • March 11, 2026

  • 0 min

Share

  • 1

    Epiretinal membrane (ERM) is a prevalent age-related disorder that can lead to visual dysfunction, emphasizing the need for refined prognostic stratification.

  • 2

    The study compares ERM phenotypes using microperimetry to assess parafoveal retinal sensitivity and metamorphopsia, highlighting functional differences.

  • 3

    ERM foveoschisis (ERM-F) is characterized by schisis-like spaces and distinct OCT features, necessitating its functional characterization within ERM.

  • 4

    Microperimetry (MP-3) and M-CHARTS provide sensitive assessments of parafoveal function and metamorphopsia, complementing traditional visual acuity measures.

  • 5

    This pilot study included 32 eyes categorized into three ERM groups, aiming to inform future prospective investigations on ERM phenotypes.

Original Source(s)

Evaluation of Parafoveal Retinal Function in Epiretinal Membrane Foveoschisis: A Pilot Study Comparing ERM Phenotypes via MP-3 Microperimetry

  • by Reio Sekine, Tatsuya Jujo, Kota Kakehashi, Kaito Tomokiyo, Naoto Uchiyama, Naoto Tokuda, Hiroshi Toshida, Yasushi Kitaoka

  • March 11, 2026

Related Content

Supplying Ocular Nutritional Supplements

Supplying ocular nutritional supplements (ONS) is a way to deepen patient trust and improve their visual outcomes, with the byproduct a new revenue stream. This is the theme of this issue of Optometric Management. 

Trends and Key Areas of Research in the Pathophysiology, Imaging, and Treatment of Type 3 Macular Neovascularization (MNV3) Associated with Age-Related Macular Degeneration (AMD)

UK Authorization for Aflibercept  

MHRA clears Eylea for macular edema following retinal vein occlusion

  • March 3, 2026

  • 2 min